ECM
MYGN icon

Element Capital Management’s Myriad Genetics MYGN Stock Holding History

Element Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-9,220
Closed -$424K – 803
2018
Q3 		$424K Buy
9,220
+1,307
+17% +$58.1K 0.01% 470
2018
Q2 		$296K Sell
7,913
-9,384
-54% -$317K 0.01% 554
2018
Q1 		$511K Buy
+17,297
New +$585K 0.01% 303

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Element Capital Management's MYGN Position: Q4 2018 in Review

Element Capital Management sold out of Myriad Genetics (MYGN) in Q4 2018, closing a stake of 9,220 shares — an estimated $424K sold.

Element Capital Management first reported a position in MYGN in Q1 2018 and held it in 3 quarters. The position peaked at $511K in Q1 2018. 264 funds tracked by Wall St. Rank hold MYGN as of Q4 2018.

  • Element Capital Management reported no remaining Myriad Genetics position as of Q4 2018 after selling out during the quarter.
  • Element Capital Management sold 9,220 Myriad Genetics shares in Q4 2018, an estimated $424K.
  • Element Capital Management first reported a position in Myriad Genetics in Q1 2018 and held it in 3 quarters.
  • Element Capital Management's Myriad Genetics position peaked at $511K in Q1 2018.
  • 264 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2018.

Based on Element Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.